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complication in Balloon-expendable (BE) and Self-expendable (SE) TAVI procedures
remain unclear.
Methods: 2,769 patients consecutive with a successful procedure and a predischarge
transthoracic echocardiography (TTE) were enrolled in 33 centers. Mean follow-up was
302164 days.
Results: Mean age was 837 years; 49% were female and logistic EuroSCORE was
21.513.8. BE and SE devices was implanted in 67.6% (n1872) and 32.4% (n897),
respectively. Approaches were femoral (75.4%) or non femoral: subclavian (5.6%),
transapical (17.2%) or transaortic (1.8%). A perivalvular AR2 was observed in 14.9%.
Its occurrence was 2 fold higher in SE (19.8%) than in BE-TAVI procedures (12.2%,
p0.0001). This remained significant in multivariate analysis (adjusted HR2.01,
p0.0001). A perivalvular AR2 was associated with a mortality at 1 year (24.2%) twice
higher than in patients without AR (11.9%) (p0.0001). This figure was similar for BE
(27.1% vs 12.0%) and SE-TAVI (20.5% vs 11.8%) procedures. By multivariate analysis,
a perivalvular AR2 was the strongest predictor of 1 year mortality (ad. HR2.35
[1.75-3.15]; p0.0001). This figure was similar for BE (ad. HR2.68) and SE-TAVI (ad.
HR2.10) procedures. For BE-TAVI procedures, male gender (ad. HR1.66, p0.001),
a device diameter/aortic annulus diameter Ratio 1.1 (ad. HR1.83, p0.0001) and a
femoral approach (ad. HR1.70, p0.006) were the 3 major independent predictors of
AR2. For SE-TAVI procedures, male gender (ad. HR1.61, p0.01) and a femoral
approach (ad.HR2.1, p0.008) were 2 independent predictors of AR2. Importantly,
device diameter/aortic annulus diameter Ratio was not a predictor of AR for SE-TAVI
procedures.
Conclusions: Post-procedural perivalvular AR2 was observed in 15% of successful
TAVI procedures. Its occurrence doubled the 1-year mortality rate and was the strongest
and independent predictor of 1-year mortality for both BE and SE-TAVI procedures.
Analysis of predictors of AR suggests that device-type and procedural characteristics may
impact the occurrence of AR.
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Background: The presence of mitral regurgitation (MR) is an independent predictor of
mortality after conventional aortic valve replacement for aortic stenosis. The predictive
value of pre-procedural MR on clinical outcome after TAVI is unknown.
Methods: 3,195 consecutive patients were enrolled in 33 centres. MR was graded
according to pre-procedural transthoracic echocardiography (TTE) as none/trivial(0),
mild(1), moderate(2), moderate-to-severe(3), or severe(4). The mean age was
827 years; 49% were female and mean logistic EuroSCORE was 21.914.3. Balloon
(BE) and self-expendable (SE) devices were implanted in 66.9% and 33.1% of patients,
respectively. Approaches were transarterial (transfemoral: 74.6%; subclavian: 5.8%),
transapical (17.8%), and transaortic (1.8%).
Results: Pre-procedural TTE showed no MR in 32% of cases, a grade 1 MR in 46% of
cases, a grade 2 MR in 20% of cases and a grade 3-4 in 2% of cases. Procedural success
rate was 96.9%. Actuarial 1 year mortality was 19.5%. By univariate analysis, pre-
procedural MR grade2, MR Grade1 and MR Grade0 were associated with a 1 year
mortality of 24.0%, 20.1% and 15.8%, respectively (p0.002). By multivariate analysis,
4 independent baseline characteristics were associated with preprocedural MR: a higer
Logistic EuroSCORE (p0.0001), a lower ejection fraction (p0.0002), a higher NYHA
class (p0.0007), and female gender (p0.001). By multivariate Cox analysis, indepen-
dent predictors of one-year mortality were: logistic EuroSCORE (p0.0001), NYHA
class (p0.0001) and transapical approach (p0.0005). The presence of preprocedural
MR was not significantly associated with 1-year mortality (p0.31). Results did not differ
when analyses were restricted only to BE or only to SE devices.
Conclusions: A mild(grade1) or a moderate(grade 2) MR preprocedural is associated
with a higher 1-year mortality after TAVI. However, since preprocedural MR is
associated with a higher NYHA class or a higher logistic Euroscore, pre-procedural MR
is not an independent predictor of mortality. These findings suggest that, in itself, the
presence of a mild or a moderate MR should not refrain from performing TAVI and
should not impact the type of valve to be used.
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Background: The Placement of Aortic Transcatheter Valves (PARTNER) trial Cohort A
demonstrated similar survival after transcatheter and surgical aortic valve replacement
(TAVR and SAVR, respectively) in high-risk operable patients with symptomatic, severe
aortic stenosis (AS). The impact of valve replacement technique on left ventricular (LV)
function and the effects of LV dysfunction on clinical outcomes are unknown.
Methods: The PARTNER trial randomized high-risk patients with severe AS to TAVR
or SAVR. Echocardiographic evaluation was performed at baseline, hospital discharge,
1-, 6-, and 12-months. Patients were stratified by the presence of LV dysfunction
(LVEF50%).
Results: In patients with LV dysfunction (N215), mean LV ejection fraction (LVEF)
increased from 369 to 4912% 1-year after TAVR and from 389 to 4912% after
SAVR (pNS). At 1-year, LVEF was unchanged in patients with preserved LV function
(N454) in both treatment groups. All-cause mortality was similar for TAVR and SAVR
at 30-days and 1-year regardless of baseline LV function and valve replacement technique
(Figure). Rates of repeat hospitalization at 1-year follow-up were comparable with TAVR
and SAVR in patients with reduced (25.6 vs17.1%, pNS) and preserved (11.7 vs 14.8%,
pNS) LV function, as were functional class and 6-minute walk test.
Conclusions: In high-risk patients with severe AS and LV dysfunction, improvements in
LVEF were similar after TAVR and SAVR. Mortality rates were comparable between
valve replacement techniques regardless of LV function.
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Background: The outcomes of severe aortic stenosis (AS) patients with chronic
obstructive pulmonary disease (COPD) undergoing transcatheter aortic valve replacement
(TAVR) have not been systematically studied. The present study aimed to evaluate the
impact of COPD on the outcome of patients treated for severe AS across all treatment
modalities.
Methods: All patients included in the PARTNER trial and who underwent TAVR,
including continued access patients, (n1938) were evaluated for outcome according to
COPD severity, stratified into no COPD, non-oxygen-dependent (non-O2 dep) COPD and
oxygen-dependent (O2 dep) COPD. Outcomes of COPD patients in the different study
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arms were compared: cohort A patients (high-risk) treated by either TAVR (n149) or
surgical aortic valve replacement (SAVR, n138); and cohort B patients (considered
inoperable) treated by either TAVR (n72) or medical therapy only (MedTx, n95).
Results: In the total group of patients included in the PARTNER trial who underwent
TAVR, those having no COPD (n1096) and non-O2-dep COPD (n627) had better
1-year survival than did O2-dep COPD patients (n215). (Table) O2-dep COPD patients
who underwent TAVR and survived for 1 year had relatively low rates of high functional
class (NYHA class I/II): 79.2% of cohort A patients; 52.4% of cohort B. There were no
differences in baseline characteristics between the TAVR and control groups in the
different subgroups evaluated. In cohort A patients, 1-year outcomes did not differ
significantly between TAVR and SAVR. In cohort B patients, TAVR, compared to
MedTx, improved 1-year survival free of hospitalization but not 1-year survival. (Table)
Conclusions: Patients with severe COPD and severe AS are at higher risk for worse
clinical outcome and lower survival. In COPD patients, TAVR had better outcome than
did medical therapy but showed no benefit over SAVR.
All TAVR patients COPD patients (TAVR vs. control)
No
COPD
n1096
non-O2dep
COPD
n627
O2 dep
COPD
n215
p
Value
TAVR
n149
SAVR
n138
p
Value
TAVR
n72
MedTx
n95
p
Value
1-year survival
(%)
85.0 84.1 76.9 0.02 75.0 73.1 0.60 62.5 47.8 0.12
1-year survival
free from
hospitalization
(%)
79.2 78.3 69.7 0.01 65.5 63.0 0.57 51.4 30.1 0.03
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Background: The PARTNER Trial demonstrated that transcatheter aortic valve replace-
ment (TAVR) in high surgical risk patients with aortic stenosis was non-inferior to
surgical AVR. Whether there are gender-specific differences in the application of TAVR
to this high-risk population are unknown.
Methods: Patients enrolled in the high-surgical risk cohort of the PARTNER Trial
(Cohort A) were included in this analysis (n697). Gender-specific differences in baseline
characteristics and outcomes at 2 years of follow-up were compared by randomized
treatment assignment.
Results: Despite greater age (84.9 vs. 83.4, p0.01), and slightly higher median STS
scores (11.1 vs. 11.0, p0.03), women (n298) had a lower prevalence of important
comorbidities, including diabetes (35.6% vs. 45.6%, p0.01), smoking history (33.2% vs.
60.7%, p0.001), coronary artery disease (64.4% vs. 83.7%, p0.001), prior CABG
(19.8% vs. 60.4%, p0.001), peripheral vascular disease (36.4% vs. 46.9%, p0.01), and
chronic kidney disease (11.7% vs. 23.9%, p0.001). There were no differences in
outcomes at 30 days between TAVR and surgery in women; among TAVR patients, there
were similar rates of both mortality (4.1% vs. 3.0%, p0.58) and stroke (5.5% vs. 4.0%,
p0.52) in women compared to men. Compared to surgery, women undergoing TAVR
had better one (18.5% vs. 29.5%, p0.02) and 2-year (28.6% vs. 38.6%, p0.05)
survival, whereas, among men, there was no difference at either one (28.5% vs. 25.2%,
p0.67) or 2 years (37.5% vs. 32.1%, p0.43). Compared to surgery, women undergoing
TAVR had higher stroke rates at 1 year (7.1% vs. 0.7%, p0.01); this difference was not
seen in men (5.3% vs. 5.0%, p0.90). There was a significant treatment-gender
interaction for mortality and stroke at 1 but not 2 years, with no significant interactions for
other outcomes.
Conclusions: Gender-specific differences in outcomes (beyond 30 days) were observed
among randomized patients in PARTNER suggesting TAVR may be the preferred
therapy among women. Further investigation is required to determine whether this benefit
can be attributed specifically to gender, or whether other factors may be involved.
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Background: Female sex is associated with adverse outcomes following conventional
aortic valve replacement. We investigate gender differences following transcatheter aortic
valve implantation (TAVI) in the UK’s National Institute for Cardiovascular Outcomes
Research (NICOR) TAVI Registry.
Methods: Retrospective analysis of 1627 patients enrolled in a UK multicentre registry
from January 2007 to December 2010. TAVI was conducted via transfemoral, transapical,
subclavian/transaxillary and transaortic access routes with implantation of Medtronic
CoreValve ReValving System®, Edwards SAPIENTM and SAPIEN XTTM devices.
Results: TAVI was performed in 756 (46.5%) females and 871 (53.5%) males aged
82.66.8 years and 80.87.6 years respectively. Females had a higher peak aortic
gradient (84.428.6mmHg v 76.624.5mmHg; p0.001) and smaller aortic annulus
diameter (21.12.8mm v 23.03.1mm; p0.001). Men had greater prevalence of type
II diabetes (23.9% v 19.2%; p0.021), poor left ventricular systolic function (11.9% v
5.5%; p0.001), three vessel coronary artery disease (19.4% v 9.2%; p0.001), left main
stem disease (8.0% v 3.2%; p0.001), previous myocardial infarction (29.5% v 13.0%;
p0.005), peripheral vascular disease (32.4% v 23.3%; p0.001) and higher logistic
EuroSCORE (21.814.2% v 21.013.4%; p0.046). Kaplan-Meier mortality at 30 days was
6.3% (95% CI 4.3% to 7.9%) in women and 7.4% (5.6% to 9.2%) in men. At 6 months, 14.1%
(11.5% to 16.7%) and 16.6% (14.0% to 16.6%) respectively. At 1 year 21.9% (18.7% to
25.1%) and 22.4% (19.4% to 25.4%) respectively. There was no difference in mortality:
p0.331 by log-rank test; hazard ratio for women 0.911 (0.754 to 1.100). There was no
difference in device success rate (96.6% in women v 96.4% in men; p0.889) or cerebro-
vascular event rate at 30 days (3.8% v 3.7%; p0.962). However, women had significantly
more major vascular complications than men (7.5% v 4.2%; p0.004).
Conclusions: Despite a higher risk profile in males there was no difference in mortality,
procedural success or cerebrovascular event rate between genders. However, women had
almost twice the rate of major vascular complications compared with men.
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Background: Background Paravalvular regurgitation (PVR) after transcatheter aortic
valve replacement (TAVR) is associated with adverse outcomes. Studies evaluating the
utility of three-dimensional echo (3DE) are limited. We performed a retrospective analysis
using 3DE-derived annular measurements and evaluated their ability to predict PVR.
Methods: 58 TAVR patients were evaluated: 35 patients who receive a post-dilatation for
paravalvular regurgitation (PD) and 23 who did not (NoPD). Intra-procedural trans-
esophageal echocardiography was performed with both two-dimensional (2DE) and 3DE
imaging. PVR areas seen on a short axis view were measured immediately following
deployment. Pre-TAVR annular dimensions included the sagittal 2DE annular diameter
and 3DE measurements of: minimal diameter, maximal diameter, mean diameter, average
diameter and area. A cover index was calculated using these diameters. An area cover
index was also calculated using nominal areas of the THV and the 3DE.
Results: PD patients were more often male (p0.01) and had larger BSA (1.83 0.24
vs. 1.67 0.23 m2, p0.013) and a higher annular eccentricity index (13.6 5.1 vs.
8.01 5.3, p0.001). Following TAVR, PD patients had larger PVR areas immediately
following deployment (40.3 17.1 vs. 15.4 14.2mm2, p0.0001). These patients had
a lower cover index irrespective of the annular diameter used (Table). All measurements
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